Welcome to our dedicated page for 111 news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 stock.
111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, has announced its participation in a fireside chat with Water Tower Research on September 5, 2024, at 11:00 a.m. ET. The event will feature Junling Liu, Co-Founder, Chairman, and CEO of 111, discussing the company's Q2 2024 earnings, strategic plans for the second half of 2024, and recent technological innovations, including AI applications in its supply chain platform.
The fireside chat will be conducted by Robert Sassoon, senior research analyst at Water Tower Research. Interested parties can register for this listen-only event through the provided registration link. A replay of the discussion will be available on 111's investor relations website under the 'Events' section.
111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, has announced it will report its unaudited financial results for the second quarter ended June 30, 2024, before the U.S. market opens on Thursday, August 29, 2024. The company will host an earnings conference call at 7:30 AM U.S. Eastern Time on the same day.
Participants are required to register in advance using the provided link. Upon registration, they will receive dial-in details, passcode, and a unique access PIN. A live and archived webcast of the conference call will be available on the company's website. Additionally, a telephone replay of the call will be accessible until September 5, 2024.
111, Inc. (NASDAQ: YI), a tech-enabled healthcare platform company in China, has appointed Grant Thornton Zhitong Certified Public Accountants LLP as its new independent registered public accounting firm. This change, effective July 19, 2024, replaces Deloitte Touche Tohmatsu Certified Public Accountants LLP. The decision was made after careful evaluation and approved by 111's board of directors and audit committee.
Grant Thornton will audit and report on 111's consolidated financial statements for the year ending December 31, 2024, as well as assess the effectiveness of the company's internal control over financial reporting. This change in auditors represents a significant shift in 111's financial oversight and reporting processes.
111, Inc. (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, has announced its participation in a fireside chat with Water Tower Research on July 18, 2024, at 2:00 p.m. ET. The event will feature Junling Liu, Co-Founder, Chairman, and CEO of 111, who will discuss the company's:
- Business model
- Strategic goals
- Competitive landscape and advantages
- Growth drivers
- Market opportunities
The fireside chat is a listen-only event, and interested parties can register using the provided link. A replay will be available on 111's investor relations website under the 'Events' section.
111, a leading tech-enabled healthcare platform, has entered into a strategic partnership with Beijing Scrianen Pharmaceutical to expand nationwide reach and improve drug accessibility. This collaboration will enhance their existing relationship, leveraging big data, digital marketing, and cloud services to make Scrianen's products, including Scrianen Folic Acid Tablets, more accessible both online and offline.
Since 2017, 111 has been a partner in Scrianen's Authentic Alliance. 111 operates an integrated healthcare ecosystem comprising online and offline pharmacies, digital distribution, and SaaS-based services. The partnership aims to utilize both companies' resources to deliver higher-quality healthcare products to a broader audience in China.
111 announced its unaudited financial results for Q1 2024, achieving operational profitability for the first time with an operating income of RMB3.7 million. Net revenues were RMB3.5 billion, down 4.6% YoY due to high demand in Q1 2023. Operating expenses decreased 20.6% to RMB204.8 million, improving operational efficiency. Non-GAAP income rose to RMB8.9 million, a 259.2% increase. However, net loss was RMB2.7 million, down from RMB19.4 million YoY. Cash and equivalents stood at RMB627.3 million. The company plans to increase operational efficiency and market share through technology and cost-saving logistics innovations.
111, Inc. (NASDAQ: YI) will release its unaudited financial results for Q1 2024 on May 23, 2024. The company aims to digitally connect patients with medicine and healthcare services in China. The earnings conference call will take place at 7:30 AM U.S. Eastern Time on the same day.
Summary not available.
Summary not available.
Summary not available.